AR061847A1 - Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas. - Google Patents

Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.

Info

Publication number
AR061847A1
AR061847A1 ARP070103039A ARP070103039A AR061847A1 AR 061847 A1 AR061847 A1 AR 061847A1 AR P070103039 A ARP070103039 A AR P070103039A AR P070103039 A ARP070103039 A AR P070103039A AR 061847 A1 AR061847 A1 AR 061847A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
optionally substituted
heteroaryl
nra
Prior art date
Application number
ARP070103039A
Other languages
English (en)
Inventor
Colleen Gritzen
Richard M Soll
Glenn Noronha
Ved P Pathak
Jianguo Cao
Joel Renick
Binqi Zeng
Pherson Andrew Mc
Original Assignee
Targe Gen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targe Gen Inc filed Critical Targe Gen Inc
Publication of AR061847A1 publication Critical patent/AR061847A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas que los comprenden y uso como inhibidores de quinasas. Reivindicacion 1: Un compuesto caracterizado porque responde a la estructura en donde: G1 se selecciona entre un grupo que consiste de un enlace, H, un arilo opcionalmente sustituido, o un heteroarilo opcionalmente sustituido; L1 se selecciona entre el grupo que consiste de O, SO, SO2, SO2-alquilo, SO2NH, CO, C(O)NH, SO2NH-alquilo, CO-alquilo, C(O)NH-alquilo, OC(O); C(O)O, alquilo opcionalmente sustituido, alquilo ramificado, aminoalquilo, alcoxi, o hidroxialquilo; L2 se selecciona entre el grupo que consiste de H, alquilo opcionalmente sustituido, alquilo ramificado, aminoalquilo, hidroxialquilo, cicloalquilo, o heterociclo; o cuando G1 es heteroarilo o H, L1 o L2 o ambos L y L2 pueden estar ausentes; A1 se selecciona entre un grupo que consiste de un enlace, NRa, C(O), S(O), S(O)2, P(O)2, O, S, y C(Ra)2, en donde si A1 es un enlace, entonces el anillo fenilo está conectado directamente al grupo A2, A2 se selecciona entre un grupo que consiste de NRa, C(O), S(O), S(O)2, P(O)2, O, y S; y la conectividad entre el anillo fenilo, A1, A2 y el anillo pirimidina son químicamente correctos; Ra se selecciona entre un grupo que consiste de H, alquilo inferior, alquilo ramificado, hidroxialquilo, aminoalquilo, tioalquilo, alquilhidroxilo, alquiltiol, y alquilamino; R3 se selecciona en forma independiente en cada caso de un grupo que consiste de hidrogeno, alquilo, alquilo ramificado, alcoxi, halogeno, CF3, ciano, alquilo sustituido, hidroxilo, alquililhidroxilo, tiol, alquiltiol, tioalquilo, amino, y aminoalquilo; n es un entero que tiene un valor entre 0 y 4 inclusive; L3 y L4 son cada uno en forma independiente seleccionados entre un grupo que consiste de NH, NRa, NHCH2, NHCHRa, NHC(Ra)2, N(O), C(O), S(O), S(O)2, OS(O)2, O, CH2, CHRa, (CRa)2, P(O), OP, OP(O), OP(O)2, P(O)NH, P(O)NRa, P(O)2NH, C(O)NH, C(O) NRa, NHC(O), CNRaC(O), NHS(O), NRaS(O), NHS(O)2, NRaS(O)2, NHP(O), y NRaP(O)2; cada uno de s y t es un entero en forma independiente con un valor de 0 o 1, la salvedad de que si s = 0, entonces t = 1, y si t = 0, entonces s = 1: y L5 se selecciona entre un grupo que consiste de alquilo inferior, alquilo ramificado, CF3, cicloalquilo, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, arilo bicíclico, heteroarilo bicíclico, bicíclico donde uno de los anillos es arilo o heteroarilo y el otro anillo es nonarilo, y bicíclico donde ambos anillos son nonarilo; en donde un arilo opcionalmente sustituido o heteroarilo, en forma independiente en cada caso, puede estar sustituido en 1, 2, 3, o 4 carbonos con alquilo, alquilo ramificado, alcoxi, halogeno, CF3, ciano, alquilo sustituido, hidroxilo, tiol, alquiltiol, tioalquilo, amino, y aminoalquilo; y sales aceptables para uso farmacéutico, hidratos, solvatos, prodrogas, estereoisomeros, N-oxidos o sus formas cristalinas.
ARP070103039A 2006-07-07 2007-07-06 Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas. AR061847A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81917006P 2006-07-07 2006-07-07
US11/772,572 US8030487B2 (en) 2006-07-07 2007-07-02 2-amino—5-substituted pyrimidine inhibitors

Publications (1)

Publication Number Publication Date
AR061847A1 true AR061847A1 (es) 2008-09-24

Family

ID=38923534

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103039A AR061847A1 (es) 2006-07-07 2007-07-06 Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.

Country Status (4)

Country Link
US (1) US8030487B2 (es)
AR (1) AR061847A1 (es)
TW (1) TW200819439A (es)
WO (1) WO2008008234A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003477A (es) * 2002-10-03 2005-07-22 Targegen Inc Agentes vasculo-estaticos y metodos de uso de los mismos.
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
RU2006139258A (ru) 2004-04-08 2008-05-20 Таргеджен, Инк. (US) Бензотриазиновые ингибиторы киназ
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011788B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
WO2007127366A2 (en) * 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
EA200900072A1 (ru) * 2006-07-07 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
US20100240657A1 (en) * 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
CL2008001943A1 (es) * 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
WO2009137052A1 (en) * 2008-05-05 2009-11-12 Winthrop University Hospital Method for improving cardiovascular risk profile of cox inhibitors
AU2009295855A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh Antiproliferative compounds
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
ES2940885T3 (es) 2009-06-12 2023-05-12 Abivax Compuestos útiles para tratar el envejecimiento prematuro y en particular la progeria
EP2261214A1 (en) * 2009-06-12 2010-12-15 Splicos Sas Compounds useful to treat premature aging and in particular progeria
US9144557B2 (en) * 2009-10-13 2015-09-29 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B−rafキナーゼインヒビター
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN103073508B (zh) * 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
US9782406B2 (en) 2011-10-25 2017-10-10 Peking University Shenzhen Graduate School Kinase inhibitor and method for treatment of related diseases
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
AU2013227139B2 (en) * 2012-02-28 2017-02-16 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CA2882158A1 (en) * 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
EP2712862A1 (en) * 2012-09-28 2014-04-02 Splicos New anti-invasive compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
CN104109127B (zh) * 2013-04-19 2019-11-05 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
ME03015B (me) 2013-04-19 2018-10-20 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
HRP20211839T1 (hr) 2013-07-05 2022-03-04 Abivax Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
JP6113633B2 (ja) * 2013-11-27 2017-04-12 株式会社ジャパンディスプレイ 有機el表示装置及びその製造方法
WO2015084749A1 (en) * 2013-12-02 2015-06-11 The Trustees Of Columbia University In The City Of New York Modulating ferroptosis and treating excitotoxic disorders
CN103992262B (zh) * 2014-06-12 2015-11-11 苏州明锐医药科技有限公司 塞瑞替尼及其中间体的制备方法
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA51229A (fr) 2015-02-20 2021-03-24 Incyte Corp Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
CN104817487B (zh) * 2015-05-06 2017-10-31 中国药科大学 一类可抑制表皮生长因子受体的哌啶基乙酰胺类化合物及其应用
WO2017192928A1 (en) * 2016-05-06 2017-11-09 Albany Medical College Treatment of rosacea with p38 and erk kinase pathway inhibitors
WO2018072707A1 (zh) * 2016-10-18 2018-04-26 保诺科技(北京)有限公司 芳香族醚类衍生物、其制备方法及其在医药上的应用
PT3562821T (pt) 2016-12-28 2021-03-03 Minoryx Therapeutics S L Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp FGFR inhibitor solid forms and processes for their preparation
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
CN113234026B (zh) * 2021-03-28 2024-04-30 北京大学深圳研究生院 具有b淋巴细胞酪氨酸激酶抑制活性的化合物及其应用
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
EP1150955A2 (en) * 1999-02-04 2001-11-07 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
MXPA04007637A (es) 2002-02-08 2004-11-10 Smithkline Beecham Corp Compuestos de pirimidina.
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
CN100491374C (zh) 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
NZ538715A (en) 2002-08-14 2007-07-27 Vertex Pharma Protein kinase inhibitors and uses thereof
MXPA05003477A (es) 2002-10-03 2005-07-22 Targegen Inc Agentes vasculo-estaticos y metodos de uso de los mismos.
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
EP1863794A2 (en) * 2005-03-16 2007-12-12 Targegen, Inc. Pyrimidine compounds and methods of use
WO2006133411A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
BR122021011788B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US20070149508A1 (en) 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors

Also Published As

Publication number Publication date
TW200819439A (en) 2008-05-01
US20080027070A1 (en) 2008-01-31
WO2008008234A1 (en) 2008-01-17
US8030487B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
AR061847A1 (es) Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.
AR080264A1 (es) Inhibidores ns5a de vhc
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
ES2192081T3 (es) Derivados de purina antivirales.
AR066169A1 (es) Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR056195A1 (es) Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb
CO6260132A2 (es) Derivados de oxadiazol como inhibidores de dgat
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
AR060173A1 (es) Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc.
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CO5200848A1 (es) Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
WO2006109075A3 (en) Hydroxybenzamide derivatives and their use as inhibitors of hsp90
CO6160312A2 (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico
CO5690582A2 (es) Derivados de n-tiazol-2-il-benzamida
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
WO2005075458A8 (en) Pyrimidine derivatives as orexin receptors antagonists
AR071452A1 (es) Inhibidores de hsp90
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
WO2008007122A3 (en) Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
CO6361956A2 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmaceúticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure